Gandara Esteban, Moniz Thomas T, Ungar Jonathan, Lee Jason, Chan-Macrae Myrna, O'Malley Terrence, Schnipper Jeffrey L
Division of General Medicine and Primary Care, Brigham and Women's Hospital, Boston, USA.
Jt Comm J Qual Patient Saf. 2008 Aug;34(8):460-3. doi: 10.1016/s1553-7250(08)34057-4.
Anticoagulation is a commonly prescribed and effective therapy for several medical conditions but requires detailed communication among clinicians to avoid adverse patient outcomes following hospital discharge.
Discharge documentation packets of a sample of patients discharged from all five acute care hospitals of the Partners Healthcare System to 30 subacute facilities in Boston and prescribed anticoagulation for treatment or prophylaxis of thromboembolic disease were evaluated. Required data elements included information on anticoagulation indication, duration, dosing, monitoring, and follow-up. Discharge documentation packets were randomly selected for reviewers at acute sites, whereas reviewers at subacute sites selected which packets to review.
Of 757 patients prescribed anticoagulation at discharge from March 2005 through June 2007, duration of therapy (for unfractionated or low-molecular-weight heparin [UFH/LMWH]) and recent dosing and monitoring information (for warfarin) were the areas with the biggest deficits. Of the patients prescribed UFH/LMWH or warfarin, 45.4% and 16.4%, respectively, had all the required information in the discharge summary. Patients discharged from community hospitals were more likely to be discharged with all the information needed for the use of warfarin (Odds Ratio [OR], 2.56; 95% confidence interval [CI], 1.20-5.46) or UFH/LMWH (OR, 2.97; 95% CI, 1.98-4.44) than patients discharged from academic medical centers.
Important information to safely prescribe anticoagulation after discharge was often missing from the discharge summaries of patients transferred from acute hospitals to subacute facilities. Future research should focus on developing, implementing, and evaluating quality improvement interventions to address this gap.
抗凝治疗是针对多种病症常用的且有效的治疗方法,但临床医生之间需要进行详细沟通,以避免患者出院后出现不良后果。
对从合作医疗系统的所有五家急症医院出院至波士顿30家亚急性医疗机构并被开具抗凝药以治疗或预防血栓栓塞性疾病的患者样本的出院文件包进行评估。所需的数据元素包括抗凝指征、疗程、剂量、监测和随访信息。急症医院的审查员随机选择出院文件包进行审查,而亚急性医院的审查员则选择要审查的文件包。
在2005年3月至2007年6月出院时被开具抗凝药的757例患者中,治疗疗程(对于普通肝素或低分子肝素[UFH/LMWH])以及近期的剂量和监测信息(对于华法林)是存在最大缺陷的方面。在被开具UFH/LMWH或华法林的患者中,分别有45.4%和16.4%在出院小结中包含了所有所需信息。与从学术医疗中心出院的患者相比,从社区医院出院的患者更有可能在出院时获得使用华法林(优势比[OR],2.56;95%置信区间[CI],1.20 - 5.46)或UFH/LMWH(OR,2.97;95%CI,1.98 - 4.44)所需的所有信息。
从急症医院转至亚急性医疗机构的患者的出院小结中常常缺少出院后安全开具抗凝药所需的重要信息。未来的研究应侧重于开发、实施和评估质量改进干预措施以弥补这一差距。